ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Search Videos by Topic or Participant
Browse by Series:

Ipilimumab Side Effect Management in Melanoma

Panelists: Robert H. I. Andtbacka, MD, CM, Huntsman; Omid Hamid, MD, The Angeles Clinic; Merrick I. Ross, MD, MD Anderson; Jeffrey A. Sosman, MD, Vander
Published: Friday, Aug 29, 2014
For High-Definition, Click
Experience levels with ipilimumab vary greatly, particularly in the community setting. As a result, moderator Mario Sznol, MD, encourages community oncologists who are unfamiliar with ipilimumab to contact him prior to administration. In addition to community oncologists and nurses, patients also need education on the side effects of ipilimumab, states Jeffrey A. Sosman, MD.

Side effect management remains an important aspect of treatment with ipilimumab, especially as its role continues to expand as a treatment for patients with melanoma. Clinical trials have demonstrated that ipilimumab is an effective adjuvant therapy, placing it earlier in the treatment paradigm.

Adjuvant therapy is now commonly being offered for patients with stage IIb/c melanoma, notes Omid Hamid, MD. For these patients, clinical trials exploring novel adjuvant therapies should be offered first before interferon. In many situations, patients with stage IIc melanoma do worse than those with stage IIIa, notes Jeffrey S. Weber, MD, PhD. This phenomenon suggests that the melanoma staging system needs to be changed, Weber adds.
Slider Left
Slider Right
For High-Definition, Click
Experience levels with ipilimumab vary greatly, particularly in the community setting. As a result, moderator Mario Sznol, MD, encourages community oncologists who are unfamiliar with ipilimumab to contact him prior to administration. In addition to community oncologists and nurses, patients also need education on the side effects of ipilimumab, states Jeffrey A. Sosman, MD.

Side effect management remains an important aspect of treatment with ipilimumab, especially as its role continues to expand as a treatment for patients with melanoma. Clinical trials have demonstrated that ipilimumab is an effective adjuvant therapy, placing it earlier in the treatment paradigm.

Adjuvant therapy is now commonly being offered for patients with stage IIb/c melanoma, notes Omid Hamid, MD. For these patients, clinical trials exploring novel adjuvant therapies should be offered first before interferon. In many situations, patients with stage IIc melanoma do worse than those with stage IIIa, notes Jeffrey S. Weber, MD, PhD. This phenomenon suggests that the melanoma staging system needs to be changed, Weber adds.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Community Practice Connections™: 1st Annual School of Nursing Oncology™Oct 31, 20181.5
Publication Bottom Border
Border Publication
x